Mumbai, May 12 -- Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 crore in Q4FY24. On a sequential basis, revenue increased 2% over Rs 8,358.6 crore reported in Q3FY25. Net profit also grew 13% quarter-on-quarter from Rs 1,413.3 crore.

EBITDA for the quarter stood at Rs 2,474.9 crore, representing 29.1% of revenue.

The board recommended a final dividend of Rs 8 per equity share for the financial year 2024-25.

In its global generics business, North America contributed Rs 3,559 crore in revenue, a 9% year-on-year increase. Revenue from Europe rose 145% to Rs 1,275 crore, which includes Rs 597 crore from the newly acquired NRT business. The India business revenue grew 16% YoY to Rs 1,305 crore.

The P...